tbResList Print — Phyco Phycocyanin

Filters: qv=509, qv2=%, rfv=%

Product

Phyco Phycocyanin
Description: <p><b>Phycocyanin</b> — a water-soluble blue phycobiliprotein/chromoprotein found in cyanobacteria and red algae, best characterized as C-phycocyanin from <i>Arthrospira platensis</i> (Spirulina). It consists of α- and β-protein subunits carrying the linear tetrapyrrole chromophore phycocyanobilin. It is formally a natural-product biliprotein and food-derived bioactive rather than a conventional small-molecule drug. Standard abbreviations are PC and C-PC. Phycocyanin should be added as a separate Nestronics product because it is a chemically and functionally defined major bioactive component of Spirulina, has a substantial independent cancer literature, and is also being investigated as a photosensitizer, sonosensitizer, drug carrier, radiosensitizer, and therapeutic protein. It should not be treated as synonymous with whole Spirulina biomass.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of intrinsic and extrinsic apoptosis, including ↓ Bcl-2, ↑ Bax, mitochondrial membrane depolarization, cytochrome-c release and activation of caspases 3, 8 and 9.</li>
<li>Suppression of proliferative and survival signaling, particularly COX-2/PGE2, MAPK/ERK, PI3K/Akt/mTOR and context-dependent NF-κB signaling.</li>
<li>Cell-cycle arrest through modulation of cyclins, CDKs, p21 and p27, with G0/G1, S or G2/M arrest depending on tumor model.</li>
<li>Induction of autophagic cell death in selected cancers through inhibition of PI3K/Akt/mTOR signaling and interaction between autophagy and apoptosis pathways.</li>
<li>Inhibition of migration, invasion, angiogenesis and metastatic phenotypes, including effects on MAPK, COX-2/PGE2 and related signaling.</li>
<li>Redox modulation: C-PC is generally antioxidant in normal biological systems but can produce ↑ ROS, mitochondrial oxidative stress and GSH depletion in some cancer models; strong ROS generation also occurs when C-PC is used as a photo- or sonosensitizer.</li>
<li>Radiosensitization and chemosensitization reported preclinically, including enhancement of radiation, topotecan, cisplatin and taxane-based approaches.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> Native C-PC is a relatively large protein complex and is unstable to heat, acidic pH and gastrointestinal proteolysis. Oral intact-protein systemic bioavailability is therefore expected to be low, and digestion produces phycocyanin-derived peptides and phycocyanobilin with potentially different pharmacology. Encapsulation, nanoparticles, PEGylation and colon-targeted formulations are being investigated specifically because poor stability and delivery limit translation. Food-grade phycocyanin-rich preparations can nevertheless be consumed orally, and approximately 1 g/day phycocyanin-equivalent exposure was used for two weeks in a small human safety RCT.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer experiments expose cells directly to approximately tens to hundreds of µg/mL C-PC, with some studies using still higher concentrations. These exposures should not be assumed achievable as intact circulating C-PC after ordinary oral supplementation because gastrointestinal degradation and uncertain systemic absorption substantially separate oral exposure from direct cell-culture exposure. Photodynamic and sonodynamic applications are additionally trigger-dependent and should be evaluated separately from unactivated oral C-PC.</p>

<p><b>Clinical evidence status:</b> Preclinical for cancer treatment. Evidence includes numerous cancer-cell studies and several animal tumor models, but there is no established anticancer indication or validated therapeutic cancer dose in humans. Human exposure data mainly concern food/supplement safety rather than cancer efficacy. A small randomized safety study found a phycocyanin-rich extract providing approximately 1 g/day phycocyanin for two weeks to be well tolerated, but this does not establish anticancer efficacy. Rare IgE-mediated allergy and anaphylaxis to Spirulina/phycocyanin have been documented. Regulatory acceptance of Spirulina/phycocyanin-rich extracts as food ingredients or color additives should not be interpreted as approval of phycocyanin as a cancer drug.</p>


<h3>Phycocyanin Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mitochondrial apoptosis</td>
<td>↑ Bax/Bcl-2 ratio; ↓ mitochondrial membrane potential; ↑ cytochrome c; ↑ caspase-9 and caspase-3</td>
<td>Generally less cytotoxic in tested normal-cell models</td>
<td>Apoptotic cell death</td>
<td>One of the most reproducible anticancer effects across leukemia, breast, cervical, prostate and other models.</td>
</tr>
<tr>
<td>2</td>
<td>COX-2 and PGE2</td>
<td>↓ COX-2; ↓ PGE2</td>
<td>↓ inflammatory COX-2 activity (context-dependent)</td>
<td>↓ proliferation, inflammation and tumor-supportive signaling</td>
<td>C-PC has been described as a selective COX-2 inhibitor. COX-2 suppression is also implicated in radiosensitization and antimetastatic effects.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K Akt mTOR and autophagy</td>
<td>↓ PI3K/Akt/mTOR; ↑ autophagy (model-dependent)</td>
<td>Context-dependent</td>
<td>Growth inhibition and autophagic cell death</td>
<td>Especially well characterized in pancreatic cancer, where autophagy and apoptosis cooperate in C-PC-mediated cytotoxicity.</td>
</tr>
<tr>
<td>4</td>
<td>MAPK survival signaling</td>
<td>↓ ERK; ↑ p38/JNK or broader MAPK remodeling (model-dependent)</td>
<td>Context-dependent</td>
<td>↓ proliferation; ↑ apoptosis; ↓ migration</td>
<td>Direction varies by cancer model. Breast and pancreatic cancer studies support substantial MAPK involvement.</td>
</tr>
<tr>
<td>5</td>
<td>NF-κB survival and inflammatory signaling</td>
<td>Usually ↓ NF-κB pathway activity; occasionally ↑ NF-κB during autophagy/apoptosis balancing (model-dependent)</td>
<td>Often ↓ inflammatory NF-κB signaling</td>
<td>↓ proliferation and survival signaling</td>
<td>RIPK1/NF-κB and TIRAP/NF-κB suppression has been demonstrated in NSCLC. NF-κB responses are not uniformly unidirectional across tumor systems.</td>
</tr>
<tr>
<td>6</td>
<td>Cell-cycle control</td>
<td>↓ Cyclin D1/CDK activity; ↑ p21/p27; ↑ G0/G1, S or G2/M arrest (model-dependent)</td>
<td>Less pronounced in available comparative models</td>
<td>↓ proliferation</td>
<td>The arrest phase varies substantially with cell type and exposure conditions.</td>
</tr>
<tr>
<td>7</td>
<td>ROS and mitochondrial oxidative stress</td>
<td>↑ ROS; ↓ GSH; ↓ mitochondrial function in selected models (dose-dependent)</td>
<td>Often ↓ oxidative stress and radical burden</td>
<td>Selective redox stress and apoptosis</td>
<td>Important apparent dichotomy: C-PC is broadly antioxidant yet can become pro-oxidant in some cancer cells. ROS generation becomes much stronger with external photodynamic or sonodynamic activation.</td>
</tr>
<tr>
<td>8</td>
<td>Migration invasion and angiogenesis</td>
<td>↓ migration; ↓ invasion; ↓ angiogenic phenotype</td>
<td>Limited evidence of harmful suppression at comparable exposures</td>
<td>↓ metastatic potential</td>
<td>Reported in triple-negative breast cancer, NSCLC and other models; mechanisms overlap MAPK and COX-2/PGE2 signaling.</td>
</tr>
<tr>
<td>9</td>
<td>Radiosensitization</td>
<td>↑ radiation response; ↓ clonogenic survival</td>
<td>Relative sparing reported in tested normal colon cells</td>
<td>↑ radiation cytotoxicity</td>
<td>Preclinical colon-cancer work links the effect partly to ↓ COX-2. No established human radiosensitizer role.</td>
</tr>
<tr>
<td>10</td>
<td>Chemosensitization</td>
<td>↑ response to topotecan, cisplatin and other agents (model-dependent)</td>
<td>Potential reduction of required cytotoxic exposure remains unproven clinically</td>
<td>Enhanced combination therapy</td>
<td>Combination studies are preclinical. Mechanisms include ↑ ROS, caspase activation and altered drug-resistance pathways.</td>
</tr>
<tr>
<td>11</td>
<td>Photo and sonodynamic activation</td>
<td>↑ ROS (requires external trigger); ↓ mitochondrial membrane potential; ↑ apoptosis</td>
<td>Depends strongly on localization and trigger geometry</td>
<td>Triggered oxidative cytotoxicity</td>
<td>C-PC can function as a photosensitizer and sonosensitizer. These applications should be distinguished from unactivated C-PC pharmacology.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Direct in-vitro exposure frequently exceeds plausible intact systemic exposure after oral dosing</td>
<td>Food exposure is generally tolerated, but rare allergy including anaphylaxis is documented</td>
<td>Limits translation from cell culture to oral cancer therapy</td>
<td>Poor gastrointestinal stability, proteolysis, formulation dependence, heterogeneous preparations and absence of cancer efficacy trials are major constraints. Nanocarriers and protected delivery formulations may materially change exposure.</td>
</tr>
</tbody>
</table>

Pathway results for Effect on Cancer / Diseased Cells

NA, unassigned(tgid=0) ⓘ

NA↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   ROS↑, 7,   ROS↓, 1,   SOD2↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam?, 1,   mtDam↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 9,   Bak↑, 1,   BAX↑, 3,   Bax:Bcl2↑, 2,   Bcl-2↓, 2,   Casp↑, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   Casp9↑, 2,   CellShr↑, 1,   Cyt‑c↑, 4,   Fas?, 1,   p38↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 3,   ERK↓, 1,   ERK↑, 2,   p‑IKKα↓, 1,   JAK3↓, 1,   JNK↑, 1,   MAPK↓, 1,   mTOR↓, 1,   PI3K↓, 1,   PTEN↑, 2,   RIP1↓, 1,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 5,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 3,   DNArepair↓, 1,   P53↑, 1,   cl‑PARP↑, 1,   cl‑PARP1↑, 2,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 2,   ChrCon↑, 2,   cycE/CCNE↓, 2,   Ki-67↓, 1,   P21↑, 2,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Ki-67↓, 1,   TumCG↓, 2,   TumCP↓, 4,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   Ca+2↑, 1,   Cal9↑, 1,   COL1↓, 1,   E-cadherin↑, 3,   EMT↓, 3,   MMP2↓, 2,   MMP9↓, 4,   N-cadherin↓, 1,   TIMP2↓, 1,   TumCA↑, 1,   TumCI↓, 1,   TumCMig↓, 4,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   HIF-1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD59↑, 1,   COX2/PTGS2↓, 4,   IFN-γ↓, 1,   IL1β↓, 1,   IL2↓, 1,   IL4↑, 1,   Imm↑, 1,   MCP1/CCL2↓, 1,   MIP-1β↑, 1,   NF-kB↓, 2,   p‑p65↓, 1,   PGE2↓, 2,   TIRAP↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARα↑, 1,   PPARγ↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   BioAv↓, 1,   ChemoSen↑, 3,   Dose↝, 4,   Dose?, 1,   eff↝, 1,   eff↑, 1,   eff↓, 1,   Half-Life↓, 1,   MDR1↓, 1,   RadioS↑, 2,   selectivity↑, 5,   Synergy↑, 5,  

Clinical Biomarkers(tgid=22) ⓘ

Tumccf↓, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   chemoP↑, 2,   hepatoP↑, 1,   toxicity↓, 2,   TumVol↓, 1,   TumW↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 108

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   antiOx↓, 1,   MPO↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

TXA2↓, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   Imm↑, 2,   Inflam↓, 5,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   Dose↝, 2,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   hepatoP↑, 3,   neuroP↑, 1,   Pain↓, 1,   RenoP↑, 1,   toxicity↓, 3,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 2,  
Total Targets: 28

Research papers

Year Title Authors PMID Link Flag
2026Phycocyanin: Biomedical Activities and Related Mechanisms of ActionHongli Huang42057257https://pubmed.ncbi.nlm.nih.gov/42057257/0
2026Phycocyanin oral delivery system obtained by spray-drying with soy proteins for the treatment of inflammatory bowel diseases: in vivo evaluationFrancesca Terracina41448322https://pubmed.ncbi.nlm.nih.gov/41448322/0
2025C‑Phycocyanin induces apoptosis in oral squamous cell carcinoma KB cells via modulation of key molecular pathwaysAbbas Asoudeh‑Fard40637959https://pubmed.ncbi.nlm.nih.gov/40637959/0
2025Enhancing the gastrointestinal stability of phycocyanin through modified PEGylation: Prospects for oral anticancer treatmentYing Li41016689https://pubmed.ncbi.nlm.nih.gov/41016689/0
2025Advances about the study of phycocyanin in the treatment of breast cancer: A reviewJiajia Yu41135433https://pubmed.ncbi.nlm.nih.gov/41135433/0
2025Enhancing the bioavailability and stability of phycocyanin loaded into double-layered pectin-chitosan nanocarriersZahra Akbarbaglu41218670https://pubmed.ncbi.nlm.nih.gov/41218670/0
2025C-Phycocyanin-Cisplatin Combination Targeting Redox Balance for Enhanced Efficacy Against Glioblastoma CellsRym AkroutPMC12712674https://pmc.ncbi.nlm.nih.gov/articles/PMC12712674/0
2025pH-activated liquid microdroplet carrier for enhanced phycocyanin oral delivery and sustained bioactivity post-digestionEun Young Jeon41267234https://pubmed.ncbi.nlm.nih.gov/41267234/0
2025C-Phycocyanin induces apoptosis in oral squamous cell carcinoma KB cells via modulation of key molecular pathwaysAbbas Asoudeh-Fard40637959https://pubmed.ncbi.nlm.nih.gov/40637959/0
2021Phycocyanin from Arthrospira platensis as Potential Anti-Cancer Drug: Review of In Vitro and In Vivo StudiesSteffen BraunePMC7911896https://pmc.ncbi.nlm.nih.gov/articles/PMC7911896/0
2019C-phycocyanin: a natural product with radiosensitizing property for enhancement of colon cancer radiation therapy efficacy through inhibition of COX-2 expressionAmirhosein KefayatPMC6915779https://pmc.ncbi.nlm.nih.gov/articles/PMC6915779/0
2019Phycocyanin Exerts Anti-Proliferative Effects through Down-Regulating TIRAP/NF-κB Activity in Human Non-Small Cell Lung Cancer CellsShuai HaoPMC6627414https://pmc.ncbi.nlm.nih.gov/articles/PMC6627414/0
2019C-Phycocyanin Suppresses the In Vitro Proliferation and Migration of Non-Small-Cell Lung Cancer Cells through Reduction of RIPK1/NF-κB ActivityShuai HaoPMC6627888https://pmc.ncbi.nlm.nih.gov/articles/PMC6627888/0
2017Phycocyanin: A Potential Drug for Cancer TreatmentLiangqian JiangPMC5687155https://pmc.ncbi.nlm.nih.gov/articles/PMC5687155/0
2016In Vitro Photodynamic Effect of Phycocyanin against Breast Cancer CellsSubramaniyan BharathirajaPMC6273603https://pmc.ncbi.nlm.nih.gov/articles/PMC6273603/0
2016Clinical Safety of a High Dose of Phycocyanin-Enriched Aqueous Extract from Arthrospira (Spirulina) platensis: Results from a Randomized, Double-Blind, Placebo-Controlled Study with a Focus on Anticoagulant Activity and Platelet ActivationGitte S JensenPMC4948198https://pmc.ncbi.nlm.nih.gov/articles/PMC4948198/0
2016Phycocyanin Inhibits Tumorigenic Potential of Pancreatic Cancer Cells: Role of Apoptosis and AutophagyGaoyong LiaoPMC5046139https://pmc.ncbi.nlm.nih.gov/articles/PMC5046139/0
2015Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cellsMathangi RaviPMC4619068https://pmc.ncbi.nlm.nih.gov/articles/PMC4619068/0
2012Phycocyanin induces apoptosis and enhances the effect of topotecan on prostate cell line LNCaPMiroslav Gantar23134462https://pubmed.ncbi.nlm.nih.gov/23134462/0
2005C-phycocyanin, a very potent and novel platelet aggregation inhibitor from Spirulina platensisGeorge Hsiao16190625https://pubmed.ncbi.nlm.nih.gov/16190625/0
2003Phycocyanin-mediated apoptosis in AK-5 tumor cells involves down-regulation of Bcl-2 and generation of ROSBobbili V V Pardhasaradhi14617790https://pubmed.ncbi.nlm.nih.gov/14617790/0